TrialClinical pharmacology in drug development2020

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A Three-Part Randomized Phase 1 Study.

Arthur Bergman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.